Bi-ventricular Failure Clinical Trial
— C2 PASOfficial title:
SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection
| Verified date | October 2020 |
| Source | SynCardia Systems. LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Study Purpose The purpose of this PAS is to confirm that patients implanted with the temporary Total Artificial Heart (TAH-t) and supported with the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported with the CSS Console. The data collection mechanism for this study is the INTERMACS Registry. Study Objectives Primary Objective 1: To confirm that patients implanted with the TAH-t and supported by the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported by the CSS Console. Primary Objective 2: To compare positive outcome rates for all TAH-t patients entered in the Intermacs Registry initially supported with the Companion 2 Driver System to positive outcome rates for all TAH-t patients initially supported by the CSS Console. Primary Objective 3: To review additional data (patient survival, adverse event rates and bridge to transplant rates) to support the conclusion that the use of an artificial heart is reasonable and necessary for the treatment of irreversible biventricular failure in Medicare/Medicaid patients. Secondary Objective: - To evaluate the incidence of adverse events (AEs). The AEs will follow the definitions in the INTERMACS Registry. Study Hypothesis: Primary Objective 1 The primary hypothesis is that the positive outcome rate (defined as transplant , transfer to the Freedom Driver System support, or continuing on implant driver support, whichever occurs first; assessed at three and six months post-implant) for patients supported with the Companion 2 Driver System is non-inferior to the survival rate for patients supported with the Circulatory Support System (CSS) Console. Data Collection The data will be collected as defined in the INTERMACS Protocol and the patients will be followed at one week, one month, three months and six months or until their study endpoint is reached. Data Analysis Primary Objective 1: Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for TAH-t patients who were implanted while supported with the Companion 2 Driver System compared to TAH-t patients who were implanted while supported with the CSS Console. Primary Objective 2: Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for all TAH-t patients enrolled in the INTERMACS Registry. Phase I as described above was completed; Phase II of Study design is under review by FDA with anticipated initiation in early 2021.
| Status | Enrolling by invitation |
| Enrollment | 500 |
| Est. completion date | July 2023 |
| Est. primary completion date | December 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Implanted with the TAH-t - Patient or their legal representative has signed an informed consent (ICF) form for INTERMACS Registry participation or waiver of consent has been approved at the implanting institution. Exclusion Criteria: - Patient or legal guardian has not signed an ICF for INTERMACS Registry participation, if required at the institution. - Patient is incarcerated. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| SynCardia Systems. LLC |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Comparison of Adverse Event Rates | To evaluate the incidence of adverse events (AEs). The AEs will follow the definitions in the INTERMACS Registry. | Three and Six Months Post-TAH-t Implant or Study Endpoint, whichever occurs first. | |
| Primary | Positive outcome rates at three months and six months Post TAH-t Implant (Concurrent Cohort) | The positive outcome rates, defined as transplant, transfer to the Freedom Driver System, or continuing on implant driver support (whichever occurs first) for patients implanted on or after June 20, 2012 and supported with the Companion 2 Driver System will be compared to the positive outcome rates at three and six months for patients implanted on or after June 20, 2012 and supported with the Circulatory Support System (CSS) Console.
The analysis will include a lower one-sided 95% confidence bound on the observed survival rate for patients supported with the Companion 2 Driver system which will be compared to the CSS Console survival rate to evaluate non-inferiority. |
Three and Six Months Post-TAH-t Implant | |
| Primary | Positive outcome rates at three months and six months Post TAH-t Implant (Cumulative Cohort) | The positive outcome rates, defined as transplant, transfer to the Freedom Driver System, or continuing on implant driver support (whichever occurs first) for patients supported with the Companion 2 Driver System will be compared to the positive outcome rates at three and six months for patients supported with the Circulatory Support System (CSS) Console.
The analysis will include a lower one-sided 95% confidence bound on the observed survival rate for patients supported with the Companion 2 Driver system which will be compared to the CSS Console survival rate to evaluate non-inferiority. |
Three and Six Months Post-TAH-t Implant | |
| Secondary | Review of all TAH-t patient records in the INTERMACS Registry to confirm acceptability of treatment for bi-ventricular failure. | To review additional data (patient survival, adverse event rates and bridge to transplant rates) to support the conclusion that the use of an artificial heart is reasonable and necessary for the treatment of irreversible biventricular failure as ordered by the CMS National Coverage Decisions which requires enrollment of Medicare patients in approved studies for evidence development. | Three and Six Months Post-TAH-t Implant |